GMO Benchmark-Free Allocation Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO Climate Change Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO Emerging Domestic Opportunities Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO Emerging Markets Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO Global Asset Allocation Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO Global Equity Allocation Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO International Developed Equity Allocation Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO International Equity Allocation Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO Quality Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO Resources Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
GMO SGM Major Markets Series Fund
(A Series of GMO Series Trust)
Schedule of Investments
(showing percentage of total net assets)
November 30, 2019 (Unaudited)
Organization
Each of Benchmark-Free Allocation Series Fund, Climate Change Series Fund, Emerging Domestic Opportunities Series Fund, Emerging Markets Series Fund, Global Asset Allocation Series Fund, Global Equity Allocation Series Fund, International Developed Equity Allocation Series Fund, International Equity Allocation Series Fund, Quality Series Fund, Resources Series Fund and SGM Major Markets Series Fund (each a Fund and collectively the Funds) is a series of GMO Series Trust (the Trust). The Trust is registered under the Investment Company Act of 1940, as amended (the 1940 Act), as an open-end management investment company. The Trust was established as a Massachusetts business trust under the laws of The Commonwealth of Massachusetts on May 27, 2011. The Declaration of Trust permits the Trustees of the Trust (Trustees) to create an unlimited number of series of shares (Funds) and to subdivide Funds into classes. The Funds are diversified as that term is defined in the 1940 Act. The Funds are advised and managed by Grantham, Mayo, Van Otterloo & Co. LLC (GMO).
Each Fund invests substantially all of its assets in shares of another fund that is a series of GMO Trust and is managed by GMO (each an Institutional Fund). The performance and operations of each Fund are directly affected by the performance and operations of the relevant Institutional Fund. Each Institutional Fund, except GMO Climate Change Fund, GMO Emerging Domestic Opportunities Fund, GMO Emerging Markets Fund, GMO Quality Fund, GMO Resources Fund and GMO SGM Major Markets Fund, is a fund of funds that invests primarily in shares of other GMO Funds (underlying funds). The Funds financial statements should be read in conjunction with the financial statements of the Institutional Funds and underlying funds which have a fiscal year end of February 28/29. The financial statements of the Funds, Institutional Funds and underlying funds are available without charge on the Securities and Exchange Commissions (SEC) website at www.sec.gov or on GMOs website at www.gmo.com.
Each Fund has elected to be treated or intends to elect to be treated and intends to qualify each tax year as a regulated investment company under Subchapter M of the Internal Revenue Code of 1986, as amended. Each Fund intends to distribute its net investment income, if any, and its net realized short-term and long-term capital gains, if any, after giving effect to any available capital loss carryforwards for U.S. federal income tax purposes. Therefore, each Fund makes no provision for U.S. federal income or excise taxes.
Please see the Funds Prospectus, available on www.gmo.com, for information regarding specific risks for each Fund.
Basis of presentation
The preparation of the Schedule of Investments in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) requires GMO to make estimates and assumptions that affect the reported amounts and disclosures in the Schedule of Investments during the reporting period. GMO believes the estimates and security valuations are appropriate; however, actual results may differ from those estimates, and the security valuations reflected in the Schedule of Investments may differ from the value a Fund ultimately realizes upon the sale of those securities.
Portfolio valuation
Investments in shares of the Institutional Funds are valued at their most recent net asset value.
U.S. GAAP requires the Funds to disclose the fair value of their investments in a three-level hierarchy (Levels 1, 2 and 3). The valuation hierarchy is based upon the relative observability of inputs to the valuation of the Funds investments. The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
Changes in valuation techniques may result in transfers into or out of an investments assigned level within the fair value hierarchy. In addition, in periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition, as well as changes related to the liquidity of investments, could cause a security to be reclassified between levels.
The three levels are defined as follows:
Level 1 Valuations based on quoted prices for identical securities in active markets.
Level 2 Valuations determined using other significant direct or indirect observable inputs.
Level 3 Valuations based primarily on inputs that are unobservable and significant.
Each Fund classified its investments as Level 1 as of November 30, 2019. For a summary of valuation inputs of the Institutional Funds and underlying funds, if any, please refer to their most recent Notes to Financial Statements which are available on the SECs website at www.sec.gov or on GMOs website at www.gmo.com.
U.S. GAAP requires additional disclosures about fair value measurements for material Level 3 securities and derivatives, if any (determined by each category of asset or liability as compared to a Funds total net assets). At November 30, 2019, there were no direct material Level 3 classes of investments or derivatives with significant unobservable inputs subject to this additional disclosure.
Investments in affiliated issuers
Each fund invests substantially all of its assets in an Institutional Fund. The Funds Schedule of Investments should therefore be read in conjunction with the most recent Schedule of Investments of the Institutional Funds which are available on the SECs website at www.sec.gov.
A summary of the Funds transactions in the shares of the Institutional Funds during the period ended November 30, 2019 is set forth below:
Fund Affiliate |
Value, beginning of period |
Purchases | Sales Proceeds |
Dividend Income* |
Distributions of Realized Gains* |
Net Realized Gain (Loss) |
Net Increase/ Decrease in Unrealized Appreciation/ Depreciation |
Value, end of period |
||||||||||||||||||||||||
Benchmark-Free Allocation Series Fund | ||||||||||||||||||||||||||||||||
GMO Benchmark-Free Allocation Fund, Class III |
$ | 671,309,349 | $ | 90,114,668 | $ | 143,550,349 | $ | 414,248 | $ | 173,189 | $ | (402,722 | ) | $ | 16,502,409 | $ | 633,973,355 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Climate Change Series Fund | ||||||||||||||||||||||||||||||||
GMO Climate Change Fund, Class III |
$ | 5,746,753 | $ | 5,429,951 | $ | 75,730 | $ | 19,179 | $ | | $ | 2,503 | $ | 422,577 | $ | 11,526,054 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Emerging Domestic Opportunities Series Fund | ||||||||||||||||||||||||||||||||
GMO Emerging Domestic Opportunities Fund, Class III |
$ | 3,526,667 | $ | 896,571 | $ | | $ | 46,601 | $ | | $ | | $ | 134,970 | $ | 4,558,208 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Emerging Markets Series Fund | ||||||||||||||||||||||||||||||||
GMO Emerging Markets Fund, Class III |
$ | 15,157,466 | $ | 8,878,123 | $ | 106,649 | $ | 117,688 | $ | | $ | (6,893 | ) | $ | 786,964 | $ | 24,709,011 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Global Asset Allocation Series Fund | ||||||||||||||||||||||||||||||||
GMO Global Asset Allocation Fund, Class III |
$ | 188,298,968 | $ | 783,685 | $ | 25,642,400 | ** | $ | 783,685 | $ | | $ | 525,096 | $ | 11,290,735 | $ | 175,256,084 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Global Equity Allocation Series Fund | ||||||||||||||||||||||||||||||||
GMO Global Equity Allocation Fund, Class III |
$ | 5,342,417 | $ | 511,776 | $ | 427,525 | $ | 19,975 | $ | | $ | 45,804 | $ | 409,881 | $ | 5,882,353 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
International Developed Equity Allocation Series Fund | ||||||||||||||||||||||||||||||||
GMO International Developed Equity Allocation Fund, Class III |
$ | 12,204,583 | $ | 2,052,726 | $ | 3,754,087 | $ | 29,458 | $ | | $ | 95,587 | $ | 963,992 | $ | 11,562,801 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
International Equity Allocation Series Fund | ||||||||||||||||||||||||||||||||
GMO International Equity Allocation Fund, Class III |
$ | 235,428,006 | $ | 1,540,270 | $ | 218,703,607 | *** | $ | 859,188 | $ | | $ | (21,225,600 | ) | $ | 13,714,104 | $ | 10,753,173 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Quality Series Fund | ||||||||||||||||||||||||||||||||
GMO Quality Fund, Class III |
$ | 61,735,268 | $ | 31,085,567 | $ | 4,901,192 | $ | 178,675 | $ | 802,717 | $ | (330,153 | ) | $ | 12,061,926 | $ | 99,651,416 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Resources Series Fund | ||||||||||||||||||||||||||||||||
GMO Resources Fund, Class III |
$ | 113,128,857 | $ | 35,652,922 | $ | | $ | 155,725 | $ | | $ | | $ | (2,911,489 | ) | $ | 145,870,290 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Fund Affiliate |
Value, beginning of period |
Purchases | Sales Proceeds |
Dividend Income* |
Distributions of Realized Gains* |
Net Realized Gain (Loss) |
Net Increase/ Decrease in Unrealized Appreciation/ Depreciation |
Value, end of period |
||||||||||||||||||||||||
SGM Major Markets Series Fund | ||||||||||||||||||||||||||||||||
GMO SGM Major Markets Fund, Class III |
$ | 3,868,089 | $ | 7,028,061 | $ | 9,761,105 | $ | 76,080 | $ | | $ | (219,703 | ) | $ | (79,948 | ) | $ | 835,394 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
* | The table above includes estimated sources of all distributions paid by the Institutional Funds during the period March 1, 2019 through November 30, 2019. The actual tax characterization of distributions paid by the Institutional Funds will be determined at the fiscal year ending February 29, 2020. |
** | $14,797,269 was redeemed in-kind. |
*** | $215,917,407 was redeemed in-kind. |
Subsequent events
Subsequent to November 30, 2019, GMO SGM Major Markets Series Fund received redemption requests in the amount of $667,346.
* * *
For additional information regarding the Funds, please see the Funds most recent annual or semiannual shareholder report available on the SECs website, www.sec.gov, or visit GMOs website at www.gmo.com.